Comments on: Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein

Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein

(2021) Rouslan Kotchetkov et al.   INTERNATIONAL JOURNAL OF CANCER

Sporadic late-onset nemaline myopathy

(2019) Elie Naddaf et al.   NEUROLOGY

Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort

(2018) Mauro Monforte et al.   JOURNAL OF NEUROLOGY

Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases

(2017) Lukas J. Schnitzler et al.   Orphanet Journal of Rare Diseases

Sporadic late-onset nemaline myopathy with MGUS: Long-term follow-up after melphalan and SCT

(2014) N. C. Voermans et al.   NEUROLOGY

Sporadic late onset nemaline myopathy and immunoglobulin deposition disease

(2013) Kathrin Doppler et al.   MUSCLE & NERVE